Bayforest Capital Ltd Makes New $76,000 Investment in Dr. Reddy’s Laboratories Ltd $RDY

Bayforest Capital Ltd acquired a new position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDYFree Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,083 shares of the company’s stock, valued at approximately $76,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. National Bank of Canada FI raised its holdings in Dr. Reddy’s Laboratories by 331.2% during the 1st quarter. National Bank of Canada FI now owns 71,000 shares of the company’s stock worth $936,000 after buying an additional 54,536 shares during the period. Bessemer Group Inc. raised its holdings in Dr. Reddy’s Laboratories by 10.3% during the 1st quarter. Bessemer Group Inc. now owns 863,880 shares of the company’s stock worth $11,395,000 after buying an additional 81,024 shares during the period. Jump Financial LLC raised its holdings in Dr. Reddy’s Laboratories by 534.1% during the 1st quarter. Jump Financial LLC now owns 147,111 shares of the company’s stock worth $1,940,000 after buying an additional 123,911 shares during the period. US Bancorp DE raised its holdings in Dr. Reddy’s Laboratories by 21.5% during the 2nd quarter. US Bancorp DE now owns 197,721 shares of the company’s stock worth $2,972,000 after buying an additional 34,943 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its holdings in shares of Dr. Reddy’s Laboratories by 13.6% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 12,163,428 shares of the company’s stock valued at $182,816,000 after purchasing an additional 1,452,192 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Zacks Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.95.

Check Out Our Latest Stock Analysis on Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Trading Up 1.5%

NYSE:RDY opened at $14.44 on Friday. The stock’s 50 day moving average price is $14.30 and its 200 day moving average price is $14.31. Dr. Reddy’s Laboratories Ltd has a 52 week low of $12.26 and a 52 week high of $16.17. The company has a market capitalization of $12.05 billion, a P/E ratio of 21.87, a P/E/G ratio of 5.60 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89.

Dr. Reddy’s Laboratories (NYSE:RDYGet Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Dr. Reddy’s Laboratories had a return on equity of 17.25% and a net margin of 16.99%.The firm had revenue of $988.82 million for the quarter, compared to the consensus estimate of $88.27 billion. On average, research analysts forecast that Dr. Reddy’s Laboratories Ltd will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

(Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Featured Stories

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Ltd (NYSE:RDYFree Report).

Institutional Ownership by Quarter for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.